Pasar al contenido principal

MECANISMOS DE PATOGENESIS EN INFECCIONES AGUDAS DE SARS-COV-2 Y EN SECUELAS POST-COVID Y ESTRATEGIAS DE PROTECCION EN JOVENES Y MAYORES

PID2022-140328OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Interaction between SARS-CoV PBM and Cellular PDZ Domains Leading to Virus Virulence

  • Honrubia, José M.
  • Valverde, José R.
  • Muñoz-Santos, Diego
  • Ripoll-Gómez, Jorge
  • de la Blanca, Nuria
  • Izquierdo, Jorge
  • Villarejo-Torres, Marta
  • Marchena-Pasero, Ana
  • Rueda-Huélamo, María
  • Nombela, Iván
  • Ruiz-Yuste, Mercedes
  • Zúñiga Lucas, Sonia
  • Solá Gurpegui, Isabel
  • Enjuanes Sánchez, Luis
The interaction between SARS-CoV PDZ-binding motifs (PBMs) and cellular PDZs is responsible for virus virulence. The PBM sequence present in the 3a and envelope (E) proteins of SARS-CoV can potentially bind to over 400 cellular proteins containing PDZ domains. The role of SARS-CoV 3a and E proteins was studied. SARS-CoVs, in which 3a-PBM and E-PMB have been deleted (3a-PBM-/E-PBM-), reduced their titer around one logarithmic unit but still were viable. In addition, the absence of the E-PBM and the replacement of 3a-PBM with that of E did not allow the rescue of SARS-CoV. E protein PBM was necessary for virulence, activating p38-MAPK through the interaction with Syntenin-1 PDZ domain. However, the presence or absence of the homologous motif in the 3a protein, which does not bind to Syntenin-1, did not affect virus pathogenicity. Mutagenesis analysis and in silico modeling were performed to study the extension of the PBM of the SARS-CoV E protein. Alanine and glycine scanning was performed revealing a pair of amino acids necessary for optimum virus replication. The binding of E protein with the PDZ2 domain of the Syntenin-1 homodimer induced conformational changes in both PDZ domains 1 and 2 of the dimer., This work was supported by grants from the Government of Spain (PID2022-140328OB-I00, MCIN/AEI/10.13039/501100011033/FEDER, UE; PID2019-107001RB-I00 AEI/FEDER, UE and PIE_INTRAMURAL_LINEA 1-202020E079), CSIC (PIE_INTRAMURAL -202020E043), the European Zoonotic Anticipation and Preparedness Initiative (ZAPI) (IMI_JU_115760), the European Commission (H2020-SC1-2019, ISOLDA Project No. 848166-2), and the U.S. National Institutes of Health (NIH) (2P01AI060699). JMH received a contract from Comunidad de Madrid (Y2020/BIO- 6576, COVID-PREclinical-MODels-CM)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SARS-CoV-2-derived RNA replicons as safe and effective vaccines

  • Villarejo-Torres, Marta
  • Nombela, Iván
  • Muñoz-Santos, Diego
  • Ruiz-Yuste, Mercedes
  • Marchena-Pasero, Ana
  • Rueda-Huélamo, María
  • Ripoll-Gómez, Jorge
  • Sánchez-Cordón, Pedro J.
  • Fernández del Ama, Laura
  • Honrubia, José M.
  • Gutiérrez Álvarez, Javier
  • Hurtado Tamayo, Jesús
  • Requena-Platek, Ricardo
  • Guzmán, María
  • Casasnovas, José María
  • García-Arriaza, Juan
  • Pérez, Patricia
  • Martín-Jouve, Beatriz
  • Matamoros Grande, Tania
  • Pintado, Belén
  • Perlman, Stanley
  • Solá Gurpegui, Isabel
  • Zúñiga Lucas, Sonia
  • Enjuanes Sánchez, Luis
A collection of RNA replicons (RRs) derived from severe acute respiratory syndrome 2 (SARS-CoV-2) for use in vaccine design was constructed by genetic engineering using bacterial artificial chromosomes. A replicon, which was deleted in six genes (3a, 3c, E, 6, 7a, and 7b) was selected. Cells infected with the RR vaccine candidate led to the formation of virus-like particles that, due to the failure of being secreted, increase vaccine safety, in contrast to the wild type virions. The replicon maintained the production of RNAs encoding at least proteins S, M, and N for several days. Intranasal immunization with the RR of transgenic mice, expressing human ACE2, elicited respiratory mucosal immunity. Immunization protected against challenge with SARS-CoV-2, inducing IgG, IgM, and IgA antibodies to the spike (S) protein, the receptor binding domain, N and M proteins, and cellular immune responses (CD4+, CD8+, and long-term memory T cells). Coinfection of cells with the RR vaccine and a full-length SARS-CoV-2 led to a significant inhibition of replication of full-length virus, increasing the safety of the RR vaccine. The RR vaccine induced a minor inflammatory reaction in the absence of major side effects and was stable at different temperatures. An updated RR expressing XBB.1.5 S protein elicited neutralizing antibodies against the homologous virus and provided full protection against recent SARS-CoV-2 variants., This work was supported by grants from the Government of Spain (PID2022-140328OB-I00, MCIN/AEI/10.13039/501100011033/FEDER, UE; PID2019-107001RB-I00 AEI/FEDER), the Community of Madrid (Y2020/BIO- 6576, COVID-PREclinical-MODels-CM) Spain, the European Commission (H2020-SC1-2019, ISOLDA Project No. 848166-2), and NIH, project P01 AI060699/AI/NIAID NIH HHS/United States. J.M.H. and D.M.-S. received a contract from Community of Madrid (Y2020/BIO- 6576, COVID-PREclinical-MODels-CM). I.N.-D., M.R.-Y., M.A.R.-H., and J.R.-G. received a contract from CSIC. M.V.-T. received a predoctoral contract (FPU21/02704) for the Training of University Teachers from Government of Spain. J.M.H. received a fellowship from MCIN/ AEI/FEDER, Ref. PID2019-107001RB-I00UE. A.M.-P. received a fellowship Ref. PREP2022-0005777 from PID2022-140328OB-I00 MCIN/AEI/10.13039/ 501100011033/ FEDER, UE, RR received a fellowship from Arnhold de la Camara Foundation, Spain, and MG received a predoctoral contract (PIPF-2022/SAL-GL-24549) from Community of Madrid, Spain., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

USP24 is a cross-reactive DUB targeting MOV10 to regulate IFN-I production

  • Mukhopadhyay, Rishov
  • Draganov, Simeon D
  • Oosenbrug, Timo
  • Akkermans, Jimmy J L L
  • Kikkert, Marjolein
  • Knobeloch, Klaus-Peter
  • Fritz, Günter
  • Guzmán, María
  • Zúñiga Lucas, Sonia
  • Kim, Robbert Q
  • van der Veen, Annemarthe G
  • Kessler, Benedikt M
  • Pinto-Fernández, Adán
  • Geurink, Paul P
  • Sapmaz, Aysegul
The type I Interferon (IFN-I)-induced ubiquitin-like modifier Interferon-Stimulated Gene 15 (ISG15) plays a crucial role in the innate immune response against viral infections. ISG15 is conjugated to target proteins by an enzymatic cascade, called ISGylation. While ubiquitin-specific protease 18 (USP18) serves as the major deISGylase counteracting ISG15 conjugation, ISG15 cross-reactive deubiquitylating enzymes (DUBs) have also been reported. Here, we identify USP24 as an ISG15 cross-reactive DUB through activity-based protein profiling. USP24 processes pro-ISG15 and ISG15-linked substrates in vitro, and its depletion increases ISG15 conjugates following interferon stimulation in cells without altering canonical IFN-I signaling. USP24 knockout cells show increased IFN-β and ISG expression upon activation of cytosolic RNA sensing via viral mimicry. Proteomic analysis identifies RNA helicase Moloney leukemia virus 10 (MOV10) as a specific target of USP24 for deISGylation. Our data revealed that ISGylation of MOV10 promotes MOV10 interaction with IFIT3 and enhances IFN-β production/secretion in response to viral stimuli. This process is negatively regulated by USP24, which directly deISGylates MOV10. Our data highlight USP24's role in modulating ISGylation and IFN-I production, suggesting USP24 as a potential therapeutic agent for infectious and inflammatory diseases., This work was supported by the TRIM-NET project, which received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 813599. A.S was supported by ICI00026 from the NWO Gravity Program. S.D., A.P.F., and B.M.K. were supported by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China [grant number: 2018-I2M-2-002] and by Pfizer. Work in the A.P.F. lab was funded by Ono Pharma UK Ltd. S.Z. was supported by the Government of Spain (PID2022-140328OB-I00, MCIN/AEI/10.13039/501100011033/FEDER, UE). M.G. received a contract from Comunidad de Madrid (PIPF-2022/SAL-GL-24549). K.P.K. received funding from the German Research Foundation (DFG), Project ID DFG 423813989/GRK2606, and under Germany’s Excellence Strategy (CIBSS–EXC-2189–Project ID 390939984). T.O. and A.G.V.D.V. were supported by a research grant from the Institute for Chemical Immunology (ICI-00203 and ICI-00046), which is funded by a Gravitation project (024.002.009) from the Dutch Research Council (NWO), a VIDI research grant (09150171910070), and an Aspasia award (015.015.046) from the NWO, and the LUMC., Peer reviewed